Codexis, Inc. (CDXS) Dividend History

Company News

• Codexis’ Landmark Presentations at TIDES USA Highlight Reproducibility and Process Simplification of the ECO Synthesis Platform for Manufacturing siRNA

  Codexis presented data at TIDES USA showcasing its ECO Synthesis platform's ability to support siRNA manufacturing, including reduced purification costs, improved process performance, and potential to control stereochemistry. Three CDMOs also validated the transferability of Codexis' ligation processes.

  GlobeNewswire Inc.
• Codexis Announces Byron Dorgan to Retire from Board of Directors

  Codexis announced that Byron Dorgan will retire from the company's Board of Directors, and the company is developing its proprietary ECO Synthesis™ manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route.

  GlobeNewswire Inc.
• Specialty Enzymes Market to Expand at 7.5% CAGR, Reaching USD 10.7 Billion by 2032 | SNS Insider

  The Specialty Enzymes market is growing rapidly due to increasing applications in food, beverages, and pharmaceuticals. Advancements in science and increasing consumer knowledge of the benefits of health are key driving factors. The market is expected to reach USD 10.7 Billion by 2032, growing at a CAGR of 7.5%.

  GlobeNewswire Inc.

  Featured Companies: DD
• Global Artificial Sweeteners Market to Observe Growth at a CAGR of ~4% by 2030 | DelveInsight

  The global artificial sweeteners market is expected to grow at a CAGR of around 4% from 2024 to 2030, driven by the increasing demand for low-calorie foods due to the rising rates of diabetes, hypertension, and obesity, as well as ongoing research and development efforts leading to new product launches.

  GlobeNewswire Inc.

  Featured Companies: ADM CE IFF INGR JNJ
• Codexis Finalizes Purchase Agreement with Crosswalk Therapeutics for Gene Therapy Assets

  REDWOOD CITY, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced it has entered into an asset purchase agreement with Crosswalk Therapeutics for the Company’s investigational Fabry and Pompe disease compounds. Under the terms of the agreement, Codexis is eligible to receive future development and commercial milestone payments in addition to a low-to-mid single-digit percentage net sales-based royalty.

  GlobeNewswire Inc.